tiprankstipranks
Trending News
More News >
Biome Australia Ltd (AU:BIO)
:BIO
Australian Market

Biome Australia Ltd (BIO) AI Stock Analysis

Compare
28 Followers

Top Page

AU

Biome Australia Ltd

(Sydney:BIO)

Rating:55Neutral
Price Target:
AU$0.50
▲(6.38%Upside)
The overall stock score for Biome Australia Ltd reflects strong revenue growth but also highlights significant financial challenges, particularly in achieving profitability. The technical analysis indicates mixed market sentiment with weak momentum, while high valuation metrics suggest the stock may be overvalued in the near term without further growth. The absence of dividend yield and high P/E ratio contribute to a cautious view.

Biome Australia Ltd (BIO) vs. iShares MSCI Australia ETF (EWA)

Biome Australia Ltd Business Overview & Revenue Model

Company DescriptionBiome Australia Ltd (BIO) is a company focused on the development and commercialization of health and wellness products. Operating primarily in the nutraceutical sector, Biome Australia specializes in probiotics and complementary medicines aimed at improving digestive health and overall well-being. The company is dedicated to leveraging scientific research to create high-quality, evidence-based products that cater to a variety of health needs.
How the Company Makes MoneyBiome Australia Ltd generates revenue primarily through the sale of its health and wellness products, including probiotics and complementary medicines. The company distributes its products through various channels, including direct-to-consumer online sales, partnerships with healthcare professionals, and retail distribution. Significant partnerships with healthcare providers and retailers play a crucial role in expanding the company's market reach and driving sales. Additionally, Biome Australia may engage in licensing agreements or collaborations with other companies to develop and distribute innovative health solutions, further contributing to its earnings.

Biome Australia Ltd Financial Statement Overview

Summary
Biome Australia Ltd is experiencing significant revenue growth, but ongoing profitability challenges persist with negative net income and EBIT. Cash flows are improving but not yet positive, and the balance sheet reflects expansion with growing assets, albeit with financial stability concerns due to persistent losses.
Income Statement
60
Neutral
Biome Australia Ltd has demonstrated strong revenue growth, increasing from $866,136 in 2020 to $13,008,897 in 2024, which is a positive sign. However, the company continues to report negative EBIT and net income, indicating ongoing profitability challenges. The gross profit margin has improved, but net profit margins remain negative, suggesting that while sales are growing, costs and expenses continue to outpace revenue.
Balance Sheet
55
Neutral
The balance sheet shows a moderate debt-to-equity ratio, indicating reasonable leverage and a slight increase in stockholders' equity over time. However, the equity ratio has declined, reflecting reduced financial stability. The company's total assets and liabilities have grown, suggesting expansion, but the persistent losses impact the equity base negatively.
Cash Flow
65
Positive
Cash flow analysis reveals improvements in operating cash flow, moving from a significant deficit towards less negative figures. Free cash flow remains negative but shows improvement, which is encouraging. The company's financing activities have been robust, aiding in liquidity, but the core operations still need to generate positive cash flows to ensure long-term sustainability.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
15.86M13.01M7.24M4.11M2.32M866.14K
Gross Profit
9.58M7.91M4.06M2.38M1.07M231.21K
EBIT
-102.64K-1.67M-3.28M-4.51M-5.52M-2.61M
EBITDA
256.13K-1.58M-3.06M-4.65M-5.39M-3.25M
Net Income Common Stockholders
288.58K-1.67M-3.08M-4.54M-5.38M-3.16M
Balance SheetCash, Cash Equivalents and Short-Term Investments
2.59M2.87M2.26M5.49M9.20M473.50K
Total Assets
10.44M8.28M7.56M8.25M11.09M1.95M
Total Debt
1.22M1.30M1.15M467.05K81.00K504.53K
Net Debt
-1.36M-1.57M-1.12M-5.03M-9.12M31.03K
Total Liabilities
5.90M5.37M3.97M1.73M920.00K997.11K
Stockholders Equity
4.53M2.90M3.59M6.53M10.17M949.54K
Cash FlowFree Cash Flow
-688.81K-185.41K-3.90M-3.55M-2.46M-3.40M
Operating Cash Flow
-633.99K-163.81K-3.50M-3.42M-2.39M-3.22M
Investing Cash Flow
-190.43K-21.61K-400.94K-99.34K-28.77K-179.89K
Financing Cash Flow
1.39M793.17K665.21K8.40M2.58M3.37M

Biome Australia Ltd Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.47
Price Trends
50DMA
0.45
Positive
100DMA
0.52
Negative
200DMA
0.58
Negative
Market Momentum
MACD
<0.01
Negative
RSI
58.72
Neutral
STOCH
102.56
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BIO, the sentiment is Positive. The current price of 0.47 is above the 20-day moving average (MA) of 0.44, above the 50-day MA of 0.45, and below the 200-day MA of 0.58, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.72 is Neutral, neither overbought nor oversold. The STOCH value of 102.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BIO.

Biome Australia Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AURHT
61
Neutral
AU$18.38M140.00-3.11%89.13%69.57%
AUBIO
55
Neutral
365.388.64%60.66%
54
Neutral
$5.28B3.29-45.38%2.80%16.77%-0.08%
AUBOT
53
Neutral
AU$617.67M-56.99%10.76%-195.89%
AUIVX
43
Neutral
$9.74M-44.03%-66.59%-351.30%
AUCYP
43
Neutral
AU$38.41M-75.39%44.29%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:BIO
Biome Australia Ltd
0.47
0.15
46.87%
AU:IVX
Invion
0.12
-0.08
-40.00%
AU:CYP
Cynata Therapeutics Limited
0.17
-0.13
-43.33%
AU:RHT
Resonance Health Ltd
0.04
-0.02
-33.33%
AU:BOT
Botanix Pharmaceuticals Limited
0.32
0.04
14.29%

Biome Australia Ltd Corporate Events

Biome Australia Announces Investor Webinar to Introduce New Chair
May 28, 2025

Biome Australia Limited has announced an investor webinar scheduled for June 5th, where the company’s Managing Director, Blair Vega Norfolk, will introduce the new Chair, Geoff Sam OAM, and provide a general business update. This event reflects Biome’s ongoing commitment to engaging with investors and stakeholders, potentially impacting its market positioning by showcasing leadership changes and business strategies.

The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.

Biome Australia Announces Director Departure and Shareholding Details
May 21, 2025

Biome Australia Ltd has announced the cessation of Ilario Faenza as a director, effective May 20, 2025. Faenza held significant interests in the company, including 1,534,796 fully paid ordinary shares as a registered holder and 1,421,809 shares through FDV Investments Pty Ltd, an entity he controls. This change in directorship may impact the company’s governance and strategic direction, potentially affecting stakeholders and market perception.

The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.

Biome Australia Appoints Geoff Sam as New Chairman
May 20, 2025

Biome Australia Limited has announced the appointment of Geoff Sam as the new Chairman of the Board of Directors, following the resignation of Ilario Faenza. Geoff Sam, who brings significant expertise in healthcare and pharmaceutical manufacturing, is expected to play a crucial role in guiding Biome through its Vision 27 strategic plan and optimizing manufacturing processes. His leadership is anticipated to support the ongoing commercial development of Biome’s products both locally and internationally, aligning with the company’s growth objectives.

The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.

Biome Australia Expands Women’s Health Range with New Probiotics
Apr 30, 2025

Biome Australia Limited has announced the launch of two new products under its Activated Probiotics range, aimed at supporting women’s health. The Biome Her™ Pessary and Biome Perinatal™ Probiotic are designed to address specific health needs, such as vaginal microbiome balance and pregnancy-related health outcomes. These products are part of Biome’s strategy to capture a larger share of the growing women’s health market in Australia, where demand for complementary medicines is rising. The new offerings are expected to enhance Biome’s market positioning by catering to the leading demographic of complementary medicine consumers, thereby potentially increasing its market share and stakeholder value.

Biome Australia Reports Strong Q3 Growth and Expands Internationally
Apr 28, 2025

Biome Australia Limited reported a strong financial performance for the third quarter of 2025, with a sales revenue increase of 41% year-over-year, reaching $4.51 million. The company achieved a gross margin of 61% and recorded a net operating cash inflow of $123k, with cash receipts up 61% compared to the previous corresponding period. Biome is on track to report its first full-year net profit for FY25, marking a significant milestone in its growth trajectory. The company’s strategic expansion into international markets and the launch of its new product range, Activated Therapeutics™, are expected to further bolster its market position and stakeholder value.

Biome Australia Director Increases Shareholding
Apr 8, 2025

Biome Australia Ltd has announced a change in the director’s interest, specifically regarding Geoffrey Sam’s indirect interest in the company. The change involved an on-market purchase of 54,050 fully paid ordinary shares, increasing his holding in Annandale Super Pty Ltd to 343,025 shares. This transaction reflects a strategic move by the director, potentially indicating confidence in the company’s future performance and stability, which may impact stakeholder perceptions and market positioning.

Biome Australia Secures $5 Million NAB Debt Facility to Boost Growth
Apr 2, 2025

Biome Australia Limited has secured a $5.0 million debt facility with National Australia Bank (NAB) to accelerate its growth, replacing an existing facility with improved interest rates. The funding, divided into an Invoice Finance Facility and a Trade Finance Facility, will optimize inventory management and support both local and international business expansion, enhancing supply chain efficiencies and reducing costs. This strategic move, backed by NAB Health, underscores the bank’s confidence in Biome’s business model and its potential for international growth.

Biome Australia Reports Robust Q3 Sales and Industry Recognition
Apr 1, 2025

Biome Australia Limited reported a strong third quarter for fiscal year 2025, with sales revenue reaching approximately $4.5 million, marking a 41% increase compared to the same period last year. The company has achieved a compounded annual growth rate of 70% over the past three years and has been recognized as the retail supplier of the year by Terry White Chemmart, Australia’s largest pharmacy group. This recognition and the significant sales growth highlight Biome’s successful market positioning and operational strategy, setting a positive outlook for the remainder of the fiscal year.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.